An observational study in Primary Hypertension, sponsored by Yelda Kasımoğlu. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Yelda Kasımoğlu · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Essential Hypertension with a site in Turkey — 6 open to participants now, 6 under way, none of them phase 3. Essential Hypertension · Turkey.
Among the 21 studies in Essential Hypertension with a site in Turkey, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 17th registered.
481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →6 of the 21 studies in Essential Hypertension with a site in Turkey are open now. Recruiting first, the newest first:
Abant Izzet Baysal University · Sites in Turkey
Ages 18–65
Ardahan University · Sites in Turkey
Inonu University · Sites in Turkey
Ages 30–65
Eskisehir Osmangazi University · Sites in Turkey
Ages 25–59 · Healthy volunteers
TC Erciyes University · Sites in Turkey
Ages 18 mo–65 mo
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 718 across 71 observational studies indexed under Essential Hypertension.
Median enrollment 130 across the 19 interventional studies, 93 across the 2 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Yelda Kasımoğlu as lead sponsor.
Yelda Kasımoğlu has 1 study filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
1 of the studies in Essential Hypertension with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07577973Abant Izzet Baysal UniversityThe Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Essential Hypertension with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Children and adolescents with primary hypertension (high blood pressure without an underlying secondary cause) are at increased risk of cardiovascular disease in adulthood. Recent research suggests that not only the heart and blood vessels, but also the bacteria living in the mouth may play a role in blood pressure regulation. Certain oral bacteria can convert nitrate from food into nitrite and then into nitric oxide, a substance that helps blood vessels relax. If this nitrate-nitrite-nitric oxide pathway is impaired, blood pressure may rise.
This study aims to investigate the relationship between oral microbiota, salivary nitric oxide reductase activity and blood pressure in children and adolescents with primary hypertension compared with healthy peers. We will recruit participants aged 10-18 years who have a diagnosis of primary hypertension and an age- and sex-matched control group without hypertension.
All participants will undergo a non-invasive oral and dental examination and standardized blood pressure measurements. Saliva samples will be collected to measure pH, flow rate, nitrate and nitrite levels, total protein, lysozyme activity and to analyze the composition of oral bacteria using modern DNA-based techniques. Participants and/or their parents will also complete brief questionnaires about diet and general health.
No medication or dietary supplement will be given as part of the study, and no additional blood samples will be taken beyond routine clinical care. The main risk is minimal discomfort related to oral examination and saliva collection. There is no guaranteed direct benefit for participants; however, the results may help us better understand how oral bacteria and salivary nitric oxide pathways are linked to high blood pressure in young people. This knowledge may support the development of new non-invasive strategies for early detection and prevention of hypertension in the future.
Primary hypertension (PH) in children and adolescents is increasingly recognized as a significant public health concern. Epidemiological data from multiple cohorts, including the Young Finns Study and other long-term follow-ups, demonstrate that elevated systolic blood pressure beginning in adolescence predicts endothelial dysfunction, increased carotid intima-media thickness, and a higher lifetime risk of cardiovascular morbidity. Children with PH frequently show early subclinical changes such as impaired flow-mediated dilation, increased arterial stiffness, heightened sympathetic activity, and altered nitric oxide (NO) bioavailability. Despite these findings, the early biological mechanisms that contribute to PH in youth remain insufficiently characterized, and non-invasive biomarkers for early detection are limited.
Recent advances in pediatric cardiovascular science suggest that the nitrate-nitrite-nitric oxide (NO₃- → NO₂- → NO) enterosalivary pathway may play a previously underappreciated role in blood pressure regulation. This pathway relies heavily on commensal oral bacteria capable of reducing dietary nitrate to nitrite, which is then swallowed and converted to NO systemically. Any disruption in this oral microbial nitrate-reducing capacity, whether due to dysbiosis, impaired oral hygiene, inflammation, dietary differences, or ecological shifts during adolescence may diminish NO bioavailability and subsequently raise blood pressure. Several adult studies have shown that antibacterial mouthwashes, changes in oral microbiota composition, and reduced salivary nitrate-reducing activity lead to measurable increases in systolic and diastolic blood pressure. However, pediatric data remain extremely scarce, with no comprehensive metagenomic investigation of oral microbiota in children with PH published to date.
This study is therefore designed to characterise, in detail, the relationships between (i) salivary microbiota composition, (ii) nitrate/nitrite conversion capacity, (iii) salivary biochemical characteristics, and (iv) blood pressure profiles in adolescents aged 12-18 years diagnosed with primary hypertension. Importantly, the project employs non-invasive sampling methods (stimulated and unstimulated saliva), enabling participation from children who may not tolerate venipuncture or invasive sampling procedures, and providing a practical model for future screening tools.
Scientific Rationale and Background 1.1. Pediatric Hypertension
Primary hypertension in youth was once considered rare but now affects up to 3-5% of adolescents globally. It is strongly associated with obesity, insulin resistance, sympathetic overactivation, endothelial dysfunction, and chronic inflammatory states. Although pharmacological treatment is increasingly used, current pediatric guidelines emphasise early identification and non-pharmacological management strategies.
1.2. Oral Microbiota and Blood Pressure
The oral cavity hosts over 700 bacterial species, many of which participate in nitrate metabolism. Key nitrate-reducing genera include Veillonella, Neisseria, Rothia, Actinomyces, and Prevotella. Disturbances in these communities due to diet, oral hygiene, frequent mouthwash use, periodontal inflammation, or underlying systemic disease may reduce the efficiency of nitrate reduction.
Several human trials in adults have demonstrated that:
mouthwash-mediated suppression of nitrate-reducing bacteria acutely increases blood pressure,
dietary nitrate supplementation raises salivary nitrite levels and lowers systolic BP,
individuals with lower nitrate-reducing capacity have higher resting BP.
However, children fundamentally differ from adults in oral ecology, immune maturation, hormonal shifts during puberty, diet, and salivary gland physiology. Therefore, adult data cannot be extrapolated to pediatric populations.
1.3. Nitric Oxide, Vascular Function, and Pediatric Risk
NO is vital for vascular homeostasis. Reduced NO availability contributes to endothelial dysfunction, impaired vasodilation, increased vascular tone, and early arterial stiffness. Several pediatric studies have demonstrated:
elevated basal NO metabolites in obese children due to chronic low-grade inflammation,
disrupted NO pathways in children with early metabolic abnormalities,
correlations between salivary nitrite levels and systemic metabolic markers.
Yet, no study has simultaneously examined oral microbiome composition + nitrate reductase activity + pediatric hypertension in a unified framework.
Study Objectives and Hypotheses Primary Objective
To determine whether adolescents with primary hypertension exhibit alterations in oral microbiota composition and reduced salivary nitrate-reducing capacity compared with normotensive controls.
Secondary Objectives
To quantify salivary nitrate, nitrite, pH, flow rate, total protein, lysozyme activity and correlate these with blood pressure levels.
To explore associations between oral microbial diversity (alpha/beta diversity metrics) and hypertension status.
To identify specific bacterial taxa or functional gene pathways (via metagenomic sequencing) associated with impaired nitrate reduction.
To evaluate whether salivary microbiome features could serve as non-invasive biomarkers for early vascular risk or masked hypertension.
To explore relationships between nitrate-related pathways and anthropometric measures, oral health indices, diet, and lifestyle.
Hypotheses
Children with PH have distinct oral microbial compositions with lower abundance of nitrate-reducing bacteria.
Reduced nitrate-reducing capacity is associated with lower salivary nitrite, altered NO metabolism, and higher systolic BP.
Specific microbial signatures may predict masked hypertension and early vascular dysfunction.
Study Design
This is a observational, cross-sectional, non-interventional clinical study. No therapeutic agents or dietary supplements will be administered. All measurements rely on non-invasive, routine pediatric dental and clinical procedures.
3.1. Participants
Two groups will be recruited:
Primary Hypertension Group (PH Group)
Diagnosed according to AAP and ESH pediatric hypertension criteria.
Healthy Control Group
Age- and sex-matched.
Normotensive based on standardized clinic measurements.
3.2. Sample size
Based on prior microbiome variability estimates and effect sizes in adult nitrate-reduction studies, a minimum of 48 participants is planned (24 PH + 24 control). This number is adequate for exploratory metagenomic and metabolite correlations. Power calculations used α=0.05 and β=0.20 for differences in nitrate reduction capacity.
Data Collection Procedures 4.1. Blood Pressure Measurement
Performed using pediatric cuff-adjusted oscillometric devices validated for clinical use.
Measurements taken after 5 minutes of rest, in a seated position, using three repeated readings.
4.2. Clinical Oral Examination
Conducted by a trained pediatric dentist.
Assessment includes dental caries, gingival status, and plaque presence.
4.3. Saliva Collection (Unstimulated)
Unstimulated saliva for baseline nitrate/nitrite measurements, pH, flow rate, total protein.
Standardized collection times (morning hours, ≥1 hr after eating, drinking, brushing).
4.4. Laboratory Measurements
Biochemical analyses
Nitrate and nitrite concentrations via standardized kits (colorimetric methods).
Salivary lysozyme activity (innate immunity marker).
Total protein via BCA assay.
pH via pH strips.
Metagenomic DNA Extraction
Using a microbiome DNA extraction kit ensuring lysis of both Gram-positive and Gram-negative bacteria.
Library Preparation for NGS
Metagenomics library preparation kit
DNA barcoding kit
Library quantification and normalization using Illumina-based quantification kits.
Sequencing
Performed using Illumina MiSeq 2×300 bp paired-end sequencing.
Quality control steps include fragment size profiles, chimera removal, and adapter trimming.
Bioinformatics Pipeline
FASTQ quality filtering using QIIME2 or similar platforms.
Taxonomic classification using SILVA/Greengenes/HOMD reference databases.
Functional analysis via PICRUSt2 or equivalent tools.
Diversity analyses with Shannon, Simpson, Bray-Curtis metrics.
Data Management and Quality Assurance 5.1. Data Validation
All collected data will undergo range checks and logical consistency checks (e.g., BP ranges, anthropometric plausibility).
Automated scripts will flag inconsistencies for review.
5.2. Source Verification
Clinical data will be reviewed against patient charts by trained clinicians.
Saliva processing forms will be cross-checked with laboratory data.
5.3. Laboratory QC
Use of negative/blank controls during DNA extraction and library preparation.
Duplicate samples for \~10% of participants to assess technical variability.
Calibration logs for pipettes, thermocyclers, and sequencing equipment.
5.4. Data Security
Data stored on institutional encrypted servers behind firewall protection.
Only authorized team members will have access.
Statistical Analysis Plan 6.1. Primary Analysis
Compare microbial diversity and nitrate-reducing capacity between PH and control groups using:
Wilcoxon/Mann-Whitney U tests
PERMANOVA for beta-diversity
Differential abundance analysis (ANCOM, DESeq2)
6.2. Secondary Analyses
Spearman correlations between salivary biochemical markers and systolic/diastolic BP.
Multiple linear regression adjusting for BMI, diet, oral hygiene habits.
Exploratory machine-learning models (random forest) to identify predictive microbial features.
6.3. Missing Data Plan
Missing biochemical values handled via multiple imputation or complete case analysis.
Missing microbiome data due to low DNA yield will be documented, not imputed.
Ethical Considerations
This study involves minimal risk. No blood samples, medications, or interventions will be given. Saliva collection is non-invasive and well tolerated. Consent and assent procedures will be conducted according to institutional and national regulations.
Ethical approval was obtained from the Istanbul University Faculty of Dentistry Clinical Research Ethics Committee at its meeting dated 14/10/2025 and numbered 206.
The project may reveal novel, non-invasive microbial signatures of early vascular risk in adolescents. Findings could support:
early screening tools for masked or mild hypertension,
dietary nitrate-based preventive strategies,
better understanding of the oral microbiome-vascular axis in youth.
Participants will be recruited from children and adolescents aged 10-18 years presenting to the Istanbul University Faculty of Dentistry, Department of Pediatric Dentistry, as well as pediatric patients followed by the Pediatric Nephrology Clinic who have been diagnosed with primary hypertension. The study population includes two groups: (1) adolescents with confirmed primary hypertension, not on antihypertensive medication, and (2) age- and sex-matched healthy controls without systemic disease or blood pressure abnormalities. All participants will be systemically healthy, cooperative, and able to provide saliva samples, undergo oral examinations, and complete questionnaire assessments. Recruitment will be consecutive based on clinic attendance, and all participants and their families will be informed about study procedures before enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group includes adolescents aged 10-18 years who have been clinically diagnosed with primary hypertension based on repeated office blood pressure measurements according to pediatric hypertension guidelines. Participants will undergo standardized assessments including oral examination, blood pressure measurements, salivary collection, and laboratory analyses. Laboratory procedures include: oral microbiota profiling through 16S rRNA gene sequencing, quantification of nitrate-reducing bacterial activity, measurement of salivary pH, total protein concentration, and lysozyme activity. No therapeutic intervention will be administered. All procedures are observational and aim to characterize microbial and biochemical markers associated with primary hypertension.
Other: No active intervention
This group includes healthy adolescents aged 10-18 years with no history of primary or secondary hypertension, chronic systemic disease, or regular medication use affecting cardiovascular or oral microbiome physiology. Participants will undergo standard clinical assessments identical to the hypertension group, including oral examination, salivary collection, and blood pressure measurement. Laboratory procedures will include salivary microbiota analysis (16S rRNA sequencing), assessment of nitrate-reducing bacterial activity, salivary pH, total protein concentration, and lysozyme activity. This cohort serves as the normative comparison group to evaluate microbial and biochemical differences associated with primary hypertension. No intervention will be administered.
Other: No active intervention
This is an observational study with no active intervention. No drug, device, behavioral, dietary, surgical, or diagnostic intervention is administered to participants. All study procedures, including oral examination, salivary sampling, pH measurement, biochemical tests, and blood pressure assessment, are non-interventional and part of standard clinical evaluation. The study only aims to observe natural variations in oral microbiota composition, nitrate-reducing activity, and blood pressure without changing participants' medical care.
Microbiota Composition (16S rRNA Sequencing)
Characterization of bacterial community diversity and relative abundance in unstimulated saliva using 16S rRNA gene sequencing. Analysis will include alpha diversity, beta diversity, and differential taxa abundance between groups, with a focus on nitrate-reducing genera such as Neisseria, Rothia, and Actinomyces.
Time frame: Baseline
Salivary Nitrate and Nitrite Levels
Quantitative measurement of salivary nitrate-to-nitrite conversion capacity using colorimetric assays. The activity of nitrate-reducing oral bacteria will be assessed by determining nitrite concentrations produced in vitro from standardized nitrate substrate under controlled incubation. Higher nitrite output indicates higher nitrate-reductase activity. Values will be compared between primary hypertension patients and healthy controls.
Time frame: Baseline (single visit)
Salivary pH
Salivary acidity/alkalinity measured using validated pH indicator strips immediately after sample collection. Values will be compared between hypertensive and healthy groups.
Time frame: Baseline
Salivary Flow Rate
Unstimulated salivary flow rate (mL/min) collected over a timed period (5 minutes). Reduced flow may influence oral microbiota composition and nitrate metabolism.
Time frame: baseline
Salivary Lysozyme Activity
Quantitative assessment of innate immune enzyme lysozyme using a commercial colorimetric assay. Alterations in antimicrobial enzyme levels may influence microbial ecology.
Time frame: baseline
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.